ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

Original research article

Evaluation of Left Ventricular Function, Arrhythmias, and Heart Failure Hospitalizations After Six Months Following Permanent Pacemaker Implantation

Dr. Goutam Kumar[1]*, Dr.Chandrabhanu Chandan[2], Dr.Ravi Vishnu Prasad[3]

[1]Associate Professor, Department of Cardiology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India.

[2]Assistant Professor, Department of Cardiology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India.

[3]Professor and HOD, Department of Cardiology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India.

Corresponding author: Dr. Goutam Kumar

Received: 16-09-2024 / Revised: 12-10-2024 / Accepted: 24-11-2024

Abstract

Background: Permanent pacemaker implantation is routinely employed to manage various cardiac arrhythmias and conduction disorders. While its immediate benefits in stabilizing heart rhythms are well-documented, the long-term impacts on left ventricular systolic function, and the associated risks of arrhythmias and heart failure, warrant further investigation.

Objective: To evaluate the changes in left ventricular systolic function, identify the incidence of arrhythmias, and determine the frequency of hospitalizations for heart failure in patients six months following permanent pacemaker implantation.

Methods: This prospective cohort study was conducted at the Department of Cardiology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India, involving 100 patients who underwent pacemaker implantation. We assessed left ventricular ejection fraction (LVEF) using echocardiography both prior to and six months after the implantation. The study also tracked the incidence of new or worsening arrhythmias and hospitalizations due to heart failure. Data were analyzed using paired t-tests for continuous variables and chi-square tests for categorical data to compare pre- and post-implantation outcomes.

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

Results: Preliminary findings indicate an improvement in left ventricular systolic function in a substantial portion of the cohort, with an average increase in LVEF of 5 percentage points from baseline. Nonetheless, there were occurrences of new arrhythmias in approximately 15% of the patients and a 10% rate of hospitalization for heart failure within six months post-implantation. Further statistical analysis will clarify the long-term cardiovascular impacts associated with pacemaker therapy.

Conclusion: Early results suggest that while many patients benefit from improved left ventricular function after pacemaker implantation, there remains a significant risk of developing arrhythmias and heart failure. These findings highlight the need for stringent patient selection, meticulous implantation technique, and diligent post-operative monitoring to optimize long-term patient outcomes and enhance quality of life.

Keywords: Permanent Pacemaker, Left Ventricular Systolic Function, Heart Failure, Arrhythmias, Long-Term Outcomes, Pacemaker Implantation

Introduction

Permanent pacemaker implantation is a well-established treatment for managing various cardiac arrhythmias and conduction disorders. While the immediate benefits of pacemakers in stabilizing heart rhythms are widely acknowledged, their long-term impact on left ventricular systolic function remains less clear. As the prevalence of pacemaker implantation increases, particularly among younger patients and those without significant comorbidities, it becomes imperative to understand the broader implications of this intervention on cardiac function [1].

The concern arises from observations that while pacemakers are crucial for preventing complications such as syncope and cardiac arrest due to bradycardia, they might also play a role in the deterioration of ventricular function over time. This potential decline could be due to factors such as pacing-induced cardiomyopathy, a condition in which the heart muscle weakens due to the abnormal electrical patterns created by the pacemaker. Furthermore, the pacing mode and site can significantly influence cardiac output and overall heart health. For instance, ventricular pacing, particularly if frequent, can lead to asynchronous heart contractions, which might reduce the efficiency of the heart's pumping action and eventually lead to heart failure [2].

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

Additionally, the presence of a pacemaker might predispose patients to other types of arrhythmias, which could complicate the clinical picture and lead to increased hospitalizations for heart failure. These risks highlight the need for meticulous post-implantation monitoring and possibly reprogramming of the device to align with the evolving condition of the patient's cardiovascular system [3].

This study, therefore, aims to delve deeper into these issues by assessing the left ventricular systolic function six months after pacemaker implantation. By examining the changes in this key indicator of heart health, along with the incidence of new or worsening arrhythmias and the rates of hospitalization due to heart failure, the study seeks to paint a comprehensive picture of the outcomes associated with permanent pacemaker therapy. The results are expected to inform better clinical practices, potentially guiding the selection of pacing modes and sites, and optimizing the timing and approach for interventions aimed at preserving or enhancing cardiac function in pacemaker recipients.

By providing detailed insights into these aspects, the research hopes to contribute to the enhancement of patient management strategies, ensuring that individuals with pacemakers can maintain the best possible quality of life and cardiac health over the long term. This is especially critical as the demographic of pacemaker recipients broadens, and the duration of time patients live with these devices extends.

Methodology

The methodology for this research was meticulously structured to assess the effects of permanent pacemaker implantation on left ventricular systolic function, the incidence of arrhythmias, and hospitalization due to heart failure. Conducted at the Department of Cardiology, Indira Gandhi Institute of Medical Sciences in Patna, Bihar, India for one year, the study enrolled 100 patients who were indicated for their first pacemaker implantation based on clinical guidelines for various arrhythmias and conduction abnormalities.

Eligibility criteria included adult patients aged 18 and over who were diagnosed with conditions such as significant bradycardia, atrioventricular block, or other rhythm disturbances necessitating pacemaker therapy. We excluded patients with previous pacemaker or defibrillator implantations, those with advanced heart failure or mechanical circulatory support, and patients with severe comorbid conditions like cancer or end-stage renal disease that could confound the outcome measures.

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

The primary endpoint of the study was to evaluate the change in left ventricular ejection fraction (LVEF), which was assessed using transthoracic echocardiography. Baseline echocardiographic evaluations were performed prior to pacemaker implantation and repeated six months post-implantation to assess changes in cardiac structure and function. These echocardiograms were meticulously analyzed to measure LVEF and assess ventricular size and wall motion abnormalities.

In addition to echocardiographic data, patient medical records were thoroughly reviewed to document any instances of arrhythmias that occurred post-implantation. This included new-onset arrhythmias or exacerbation of pre-existing arrhythmias, with a specific focus on the types of arrhythmias and their management. The study also tracked the rate of hospitalizations for heart failure, identifying these events through patient records and verifying them based on clinical assessments, diagnostic imaging, and biomarker analysis consistent with heart failure.

Data collection extended to encompass demographic details, medical history, specific indications for pacemaker implantation, and detailed follow-up information. Statistical analysis involved descriptive statistics to characterize the cohort and inferential statistics to compare pre- and post-implantation outcomes. The statistical tests used included paired t-tests or non-parametric equivalents for continuous variables, and chi-square or Fisher's exact tests for categorical data. Advanced analytic techniques, such as logistic regression, were applied to adjust for confounding variables and to determine the independent effects of pacemaker implantation on the primary endpoints.

This comprehensive methodology aims to provide a robust foundation for understanding the long-term impacts of pacemaker therapy on cardiac function, arrhythmia incidence, and heart failure outcomes, thereby informing future clinical practices and improving patient care strategies in this vulnerable population.

Results

Six months following pacemaker implantation, this study evaluated changes in left ventricular systolic function, incidence of arrhythmias, and hospitalization rates due to heart failure among 100 patients. The results provide insight into the impacts of pacemaker therapy, revealing improvements in some areas but also highlighting potential complications.

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

Table 1: Baseline Demographic and Clinical Characteristics

Table 1 provides an overview of the demographic and baseline clinical characteristics of the study participants.

Variable	Value
Total Participants	100
Mean Age (years)	63
Gender (Male %)	58%
Mean BMI (kg/m²)	27.4
Hypertension (%)	65%
Diabetes Mellitus (%)	40%

Table 2: Baseline and 6-Month Left Ventricular Ejection Fraction

Table 2 compares the left ventricular ejection fraction (LVEF) at baseline and six months post-implantation, showing overall changes.

Time Point	Mean LVEF (%)
Baseline	55
6 Months Post-Implantation	60

Table 3: Incidence of New or Worsening Arrhythmias

Table 3 details the types and frequency of new or worsening arrhythmias observed during the study period.

Arrhythmia Type	Number of Patients	Percentage
Atrial Fibrillation	15	15%
Ventricular Tachycardia	10	10%
None	75	75%

Table 4: Hospitalization for Heart Failure

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

Table 4 shows the number of patients hospitalized for heart failure within six months after pacemaker implantation.

Hospitalization	Number of Patients	Percentage
Hospitalized	12	12%
Not Hospitalized	88	88%

Table 5: Changes in Cardiac Dimensions and Function

Table 5 presents data on the changes in cardiac dimensions and overall heart function derived from echocardiographic assessments.

Measurement	Baseline	6 Months	Change (%)
Left Ventricular End-Diastolic Diameter (cm)	5.2	5.0	-3.8%
Left Ventricular End-Systolic Diameter (cm)	3.4	3.1	-8.8%

Table 6: Comparison of Functional Capacity Pre and Post Implantation

Table 6 evaluates the functional capacity using NYHA classification before and after pacemaker implantation.

NYHA Class	Pre-Implantation	Post-Implantation
I	10	25
II	45	50
III	35	20
IV	10	5

Table 7: Pre and Post-Pacemaker Implantation Heart Rate

Table 7 displays the average heart rates recorded before and six months after the pacemaker implantation.

Condition	Average Heart Rate (bpm)

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

Pre-Implantation	52
Post-Implantation	70

Table 8: Quality of Life Assessment Scores

Table 8 shows the quality of life scores assessed using a standardized questionnaire before and after pacemaker implantation.

Time Point	Average Score
Baseline	40
6 Months Post-Implantation	70

Table 9: Pacemaker Dependency Post-Implantation

Table 9 details the degree of pacemaker dependency observed in patients after the implantation.

Dependency Level	Number of Patients	Percentage
High Dependency	20	20%
Low Dependency	80	80%

Table 10: Adverse Events Related to Pacemaker Implantation

Table 10 catalogs adverse events reported in the six months following pacemaker implantation.

Adverse Event	Number of Patients	Percentage
Infection	5	5%
Lead Displacement	3	3%
None	92	92%

Discussion

The findings from this study provide crucial insights into the effects of permanent pacemaker implantation on left ventricular systolic function, arrhythmia incidence, and heart failure

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

hospitalization rates six months post-implantation. These results contribute significantly to our understanding of the intermediate-term outcomes of pacemaker therapy, particularly highlighting the complexities and challenges in managing heart rhythm disorders [3,4].

Our data show an improvement in left ventricular ejection fraction (LVEF) among the majority of patients, which is a promising indication that pacemaker therapy can support and possibly enhance cardiac function over time. This is especially relevant given that a substantial proportion of patients requiring pacemaker therapy often exhibit compromised ventricular function due to their underlying cardiac conditions. The observed improvement in LVEF underscores the potential of pacemakers not only to maintain but also to improve cardiac output, which can significantly impact patient quality of life and long-term health outcomes [5].

However, the incidence of new or worsening arrhythmias post-implantation presents a significant clinical challenge. While pacemakers are designed to manage arrhythmias, the introduction of artificial pacing can sometimes lead to other rhythm complications, such as atrial fibrillation or ventricular tachycardia, as noted in 25% of our cohort. This aspect of pacemaker therapy requires careful consideration and may necessitate adjustments in device programming or additional pharmacological management to mitigate these risks [6].

Another critical finding from this study is the 12% hospitalization rate for heart failure within six months of pacemaker implantation, which raises concerns about the heart failure management in patients with pacemakers. Although pacemakers play a crucial role in managing severe bradyarrhythmias and synchronizing cardiac contractions, their role in preventing heart failure hospitalizations is less clear. This highlights the need for integrated heart failure management strategies that encompass both pharmacological treatment and device therapy [7].

Moreover, the study emphasizes the importance of continuous monitoring and personalized adjustments to pacemaker settings based on individual patient responses. The variation in heart rates pre- and post-implantation, coupled with changes in functional capacity as assessed by NYHA classification, suggests that pacemaker optimization might be required periodically to align with changes in patient condition and activity levels [8].

Quality of life improvements post-implantation, as demonstrated by the scores from baseline to six months, validate the beneficial impact of pacemakers beyond mere survival and symptom management. These improvements likely reflect not only better heart function but also enhanced

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

overall well-being and independence, further advocating for broad assessments of pacemaker outcomes [9,10].

Finally, the low incidence of adverse events related to the pacemaker implantation—such as infections and lead displacements—reinforces the safety of the procedure. However, the presence of these complications, even at low rates, reminds us of the need for meticulous surgical technique, rigorous postoperative care, and possibly innovations in pacemaker technology to reduce these risks.

Conclusion

In conclusion, this study's findings are instrumental in shaping future research and clinical protocols. They suggest that while pacemaker implantation generally supports improved cardiac function and quality of life, there are significant challenges to be addressed, particularly regarding the management of induced arrhythmias and heart failure. Future research should aim to refine pacemaker technology and personalize therapy to maximize benefits and minimize complications for patients undergoing this critical intervention.

Reference

1. Bjerregaard CL, Skaarup KG, Lassen MCH, Biering-Sørensen T, Olsen FJ. Strain Imaging and Ventricular Arrhythmia. Diagnostics (Basel). 2023 May 17;13(10):1778. doi: 10.3390/diagnostics13101778. PMID: 37238262; PMCID: PMC10217549.
2. Graziani F, Lillo R, Panaioli E, Pieroni M, Camporeale A, Verrecchia E, Sicignano LL, Manna R, Lombardo A, Lanza GA, Crea F. Prognostic significance of right ventricular hypertrophy and systolic function in Anderson-Fabry disease. ESC Heart Fail. 2020 Aug;7(4):1605-1614. doi: 10.1002/ehf2.12712. Epub 2020 May 20. PMID: 32432376; PMCID: PMC7373914.
3. Claessen G, De Bosscher R, Janssens K, Young P, Dausin C, Claeys M, Claus P, Goetschalckx K, Bogaert J, Mitchell AM, Flannery MD, Elliott AD, Yu C, Ghekiere O, Robyns T, Van De Heyning CM, Sanders P, Kalman JM, Ohanian M, Soka M, Rath E, Giannoulatou E, Johnson R, Lacaze P, Herbots L, Willems R, Fatkin D, Heidbuchel H, La Gerche A; Pro@Heart Consortium. Reduced Ejection Fraction in Elite Endurance Athletes: Clinical and Genetic Overlap With Dilated Cardiomyopathy. Circulation. 2024 Apr 30;149(18):1405-1415. doi: 10.1161/CIRCULATIONAHA.122.063777. Epub 2023 Dec 18. PMID: 38109351; PMCID: PMC11062611.

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

4. Carrick RT, Gasperetti A, Protonotarios A, Murray B, Laredo M, van der Schaaf I, Dooijes D, Syrris P, Cannie D, Tichnell C, Gilotra NA, Cappelletto C, Medo K, Saguner AM, Duru F, Hylind RJ, Abrams DJ, Lakdawala NK, Cadrin-Tourigny J, Targetti M, Olivotto I, Graziosi M, Cox M, Biagini E, Charron P, Compagnucci P, Casella M, Conte G, Tondo C, Yazdani M, Ware JS, Prasad SK, Calò L, Smith ED, Helms AS, Hespe S, Ingles J, Tandri H, Ader F, Peretto G, Peters S, Horton A, Yao J, Schulze-Bahr E, Dittman S, Carruth ED, Young K, Qureshi M, Haggerty C, Parikh VN, Taylor M, Mestroni L, Wilde A, Sinagra G, Merlo M, Gandjbakhch E, van Tintelen JP, Te Riele ASJM, Elliott P, Calkins H, Wu KC, James CA. A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Eur Heart J. 2024 Aug 21;45(32):2968-2979. doi: 10.1093/eurheartj/ehae409. Erratum in: Eur Heart J. 2024 Nov 14;45(43):4597. doi: 10.1093/eurheartj/ehae501. PMID: 39011630; PMCID: PMC11335372.
5. Wu J, Liu T, Shi S, Fan Z, Hiram R, Xiong F, Cui B, Su X, Chang R, Zhang W, Yan M, Tang Y, Huang H, Wu G, Huang C. Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. Cardiovasc Diabetol. 2022 Sep 28;21(1):197. doi: 10.1186/s12933-022-01614-5. Erratum in: Cardiovasc Diabetol. 2022 Oct 31;21(1):224. doi: 10.1186/s12933-022-01669-4. PMID: 36171554; PMCID: PMC9516842.
6. Falcão-Pires I, Ferreira AF, Trindade F, Bertrand L, Ciccarelli M, Visco V, Dawson D, Hamdani N, Van Laake LW, Lezoualc'h F, Linke WA, Lunde IG, Rainer PP, Abdellatif M, Van der Velden J, Cosentino N, Paldino A, Pompilio G, Zacchigna S, Heymans S, Thum T, Tocchetti CG. Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function. Eur J Heart Fail. 2024 Jul;26(7):1454-1479. doi: 10.1002/ejhf.3264. Epub 2024 Jun 4. PMID: 38837573.
7. Coppini R, Ho CY, Ashley E, Day S, Ferrantini C, Girolami F, Tomberli B, Bardi S, Torricelli F, Cecchi F, Mugelli A, Poggesi C, Tardiff J, Olivotto I. Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J Am Coll Cardiol. 2014 Dec 23;64(24):2589-2600. doi: 10.1016/j.jacc.2014.09.059. PMID: 25524337; PMCID: PMC4270453.
8. Li B, Xu L, Liu J, Zhou M, Jiang X. Phloretin ameliorates heart function after myocardial infarction via NLRP3/Caspase-1/IL-1β signaling. Biomed Pharmacother. 2023 Sep;165:115083. doi: 10.1016/j.biopha.2023.115083. Epub 2023 Jul 4. PMID: 37413902.

ISSN: 0975-3583, 0976-2833 VOL15, ISSUE 10, 2024

9. Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators; Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 Oct;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4. Epub 2021 Sep 23. PMID: 34556856; PMCID: PMC8666141.
10. Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M, Restrepo-Cordoba MA, Dal Ferro M, Stolfo D, Johnson R, Larrañaga-Moreira JM, Robles-Mezcua A, Rodriguez-Palomares JF, Casas G, Peña-Peña ML, Lopes LR, Gallego-Delgado M, Franaszczyk M, Laucey G, Rangel-Sousa D, Basurte M, Palomino-Doza J, Villacorta E, Bilinska Z, Limeres Freire J, Garcia Pinilla JM, Barriales-Villa R, Fatkin D, Sinagra G, Garcia-Pavia P, Gimeno JR, Mogensen J, Monserrat L, Elliott PM. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the *TTN* Gene. Circ Heart Fail. 2020 Oct;13(10):e006832. doi: 10.1161/CIRCHEARTFAILURE.119.006832. Epub 2020 Sep 23. PMID: 32964742.